The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption
of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive
breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent
the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who
require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic
armamentarium are important current challenges.
Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials
Rights & PermissionsPrintExport